文献速递贫血与红细胞疾病

艾曲泊帕联合免疫抑制治疗与新诊断儿童再生障碍性贫血的疗效比较

Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia.
PubMed 文献 · Blood Adv · 2023-01-01

该随机对照研究纳入98例初治儿童重型(SAA)和极重型(vSAA)再生障碍性贫血患者,比较艾曲泊帕(ELTR)联合免疫抑制治疗(IST)与单用IST的疗效。4个月总反应率两组相似(65% vs 53%,P=.218),但ELTR+IST组完全反应率显著更高(31% vs 12%,P=.027)。SAA亚组中ELTR+IST的总反应率更优(89% vs 57%,P=.028),vSAA亚组无差异(52% vs 50%,P=.902)。

要点

  • 4个月总反应率ELTR+IST组65% vs IST组53%,差异无统计学意义(P=.218)。
  • 完全反应率ELTR+IST组31% vs IST组12%,差异有统计学意义(P=.027)。
  • SAA亚组总反应率ELTR+IST组89% vs IST组57%(P=.028),vSAA亚组无差异(52% vs 50%,P=.902)。

核心结论

  • 在标准IST基础上加用ELTR耐受性良好,并提高了完全反应率。
  • ELTR联合IST的最大获益见于SAA患者,而未见于vSAA患者。
  • 初始未接受ELTR的患者在交叉后加用ELTR并接受第二疗程IST,获得了较高的总反应率;而初始即接受ELTR的患者第二疗程IST疗效有限。

研究设计与样本

  • 随机对照试验,纳入98例初治儿童重型(SAA)和极重型(vSAA)再生障碍性贫血患者。
  • 患者随机接受马抗胸腺细胞球蛋白(hATG)和环孢素A(CsA)联合艾曲泊帕(ELTR)(n=49)或不联合ELTR(n=49)。
  • 主要终点为4个月时的总反应率(ORR)。
  • 4个月后无反应者交叉至另一组。
  • 该试验在ClinicalTrials.gov注册,注册号为NCT03413306。

主要发现

  • 全部患者中,ELTR+IST组与IST组4个月总反应率相似(65% vs 53%,P=.218)。
  • ELTR+IST组完全反应率显著高于IST组(31% vs 12%,P=.027)。
  • SAA亚组中,ELTR+IST组总反应率优于IST组(89% vs 57%,P=.028);vSAA亚组中两组总反应率无差异(52% vs 50%,P=.902)。
  • 交叉后6个月,初始ELTR(-)患者中61%获得反应,而初始ELTR(+)患者中为17%(P=.016)。
  • ELTR+IST组与IST组3年总生存率(OS)无显著差异(89% vs 91%,P=.673),3年无事件生存率(EFS)亦无显著差异(53% vs 41%,P=.326)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) and IST alone in treatment-naïve children with severe (SAA) and very severe (vSAA) aplastic anemia. Ninety-eight pediatric patients were randomized to receive horse antithymocyte globulin (hATG) and cyclosporin A (CsA) with (n = 49) or without (n = 49) ELTR. The primary endpoint was the overall response rate (ORR) at 4 months. After 4 months, nonresponders were crossed over to the alternative group. In all patients, the ORR in ELTR + IST and IST groups was similar (65% vs 53%; P = .218); however, the complete response (CR) rate was significantly higher in the ELTR + IST group (31% vs 12%; P = .027). In severity subgroups, the ORR was 89% vs 57% (P = .028) in favor of IST + ELTR in SAA, but it did not differ in patients with vSAA (52% vs 50%; P = .902). At 6 months after the crossover, 61% of initial ELTR(-) patients achieved a response compared with 17% of initial ELTR(+) patients (P = .016). No significant difference in ELTR + IST and IST groups was observed in the 3-year overall survival (OS) (89% vs 91%; P = .673) or the 3-year event-free survival (EFS) (53% vs 41%; P = .326). There was no unexpected toxicity related to ELTR. Adding ELTR to standard IST was well tolerated and increased the CR rate. The greatest benefit from ELTR combined with IST was observed in patients with SAA but not in those with vSAA. The second course of IST resulted in a high ORR in initial ELTR(-) patients who added ELTR and had limited efficacy among patients who received ELTR upfront. This trial was registered at Clinicaltrials.gov as #NCT03413306.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Goronkova O, Novichkova G, Salimova T, et al. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. Blood Adv. 2023. PMID: 35446936. doi:10.1182/bloodadvances.2021006716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。